Rifaximin in Patients With Gastroesophageal Variceal Bleeding (RFXM)

Fudan University

Status

Completed

Conditions

Cirrhosis

Gastrointestinal Hemorrhage

Esophageal and Gastric Varices

Treatments

Drug: Rifaximin

Study type

Interventional

Funder types

Other

Identifiers

NCT02991612

ZS-CSY-RFXM

Details and patient eligibility

About

The purpose of the study is to evaluate the safety and efficacy of Rifaximin in the treatment of cirrhotic gastroesophageal variceal bleeding.

Full description

Gastroesophageal variceal bleeding is the most common and life-threatening condition in patients with portal hypertension, which are susceptibility to bacterial infection.

However, the prophylaxis use of antibiotics remained uncertain and lack of high level evidences.

Enrollment

80 patients

Sex

All

Ages

18 to 75 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

18 y.o. ≤age≤75 y.o.;
Cirrhotic gastroesophageal variceal bleeding underwent endoscopic treatment (include esophageal varices ligation, endoscopic injection sclerosis and gastric N- butyl-cyanoacrylate injection).

Exclusion criteria

age <18 y.o. or age > 75 y.o.;
Never had the variceal bleeding episode before;
Do not have endoscopic treatment;
Combined with other malignant tumors (not exclude patients with hepatocellular carcinoma who don't need treatment at the moment);
Known infection after endoscopic treatment (Fever, microbial cultures positive, et al.)
Massive ascites or combined with other high-risk factors that require prophylaxis use of antibiotics.
Acute variceal bleeding within 5 days.
Refuse to participate